文献速递艾滋病与性传播感染

序贯抗逆转录病毒治疗诱导的免疫重建骨丢失与雌激素缺乏骨丢失在小鼠模型中呈累积效应

Combined Sequential Antiretroviral Therapy-Induced Immune Reconstitution Bone Loss and Estrogen Deficiency Bone Loss Are Cumulative in Mice Models.
PubMed 文献 · J Infect Dis · 2025-01-01

研究用小鼠模型探讨抗逆转录病毒治疗诱导的免疫重建骨丢失(IRBL)与绝经后骨质疏松的交互作用。序贯而非同时进行卵巢切除与IRBL导致累积性骨丢失,椎骨骨丢失(Δ=-42.6 vs 对照,P<.01)可被阿巴西普(Δ=-13.9 vs 对照,无显著差异)和鼠李糖乳杆菌GG(Δ=-8.6 vs 对照,无显著差异)减轻。作者认为若在人体验证,早期筛查和预防或可降低绝经后HIV女性骨折风险,益生菌治疗可能提供有益替代。

要点

  • 序贯卵巢切除与IRBL在小鼠中导致累积性骨丢失,同时进行则无叠加效应。
  • 阿巴西普和鼠李糖乳杆菌GG均减轻椎骨骨丢失,但vs对照未达统计学显著。
  • 两种干预均减少骨吸收、刺激骨形成并抑制CD4+ T细胞产生TNF-α和IL-17A。

核心结论

  • 序贯IRBL与绝经后骨丢失在小鼠中呈累积效应;若在人体验证,早期筛查和预防或可降低绝经后HIV女性骨折风险,益生菌治疗可能提供有益的药物替代选择。

研究设计与样本

  • 研究采用IRBL小鼠模型,同时或序贯进行手术卵巢切除(Ovx)作为绝经后骨质疏松小鼠模型。
  • 用微型计算机断层扫描评估椎骨和股骨的皮质骨与骨小梁,用酶联免疫吸附试验检测血清骨吸收和骨形成标志物,用流式细胞术分析T细胞产生促破骨细胞因子。

主要发现

  • 同时进行Ovx与IRBL无叠加效应,而序贯Ovx与IRBL导致累积性骨丢失。
  • 联合Ovx与IRBL所致椎骨骨丢失(Δ=-42.6 vs 对照,P<.01)被抗炎药阿巴西普减轻(Δ=-13.9 vs 对照,无显著差异)。
  • 联合Ovx与IRBL所致椎骨骨丢失被鼠李糖乳杆菌GG减轻(Δ=-8.6 vs 对照,无显著差异)。
  • 阿巴西普和鼠李糖乳杆菌GG均减少骨吸收、刺激骨形成并抑制CD4+ T细胞产生促破骨细胞因子TNF-α和IL-17A。

临床怎么用

  • 作者认为若在人体验证,早期筛查和预防或可降低绝经后HIV女性的骨折风险。
  • 作者认为益生菌治疗可能提供有益的药物替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiretroviral therapy causes osteoporosis and bone fractures, increasing morbidity and mortality in people with HIV (PWH). Antiretroviral therapy induces immune reconstitution bone loss (IRBL), an inflammatory reaction associated with immune system reactivation. Women represent >50% of PWH, and many are now undergoing menopause, a major cause of postmenopausal osteoporosis that also increases fracture risk. However, the interactions between IRBL and postmenopausal bone loss are poorly understood and were investigated in this study. METHODS: We used a mouse model of IRBL, which was applied simultaneously or sequentially with surgical ovariectomy (Ovx) as a mouse model of postmenopausal osteoporosis. Cortical and trabecular bone in vertebrae and femurs was assessed with micro-computed tomography, and bone turnover was quantified by serum markers of bone resorption and formation via enzyme-linked immunosorbent assay. T-cell production of osteoclastogenic cytokines was analyzed by flow cytometry. RESULTS: Although simultaneous Ovx and IRBL did not have additive effects, sequential Ovx and IRBL caused cumulative bone loss. Vertebral bone loss from combined Ovx and IRBL (Δ = -42.6 vs control, P < .01) was blunted by the anti-inflammatory agent abatacept (Δ = -13.9 vs control, not significant) and the probiotic Lactobacillus rhamnosus GG (Δ = -8.6 vs control, not significant). Both treatments reduced bone resorption, stimulated formation, and suppressed CD4+ T-cell production of the osteoclastogenic cytokines TNF-α and IL-17A. CONCLUSIONS: Sequential IRBL and postmenopausal bone loss appear to be cumulative. If validated in humans, early screening and prophylaxis could reduce fracture risk in postmenopausal women with HIV. Probiotic therapy may provide a beneficial alternative to pharmacotherapy.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dabeer S, Tripathi AK, Weiss D, et al. Combined Sequential Antiretroviral Therapy-Induced Immune Reconstitution Bone Loss and Estrogen Deficiency Bone Loss Are Cumulative in Mice Models. J Infect Dis. 2025. PMID: 39726127. doi:10.1093/infdis/jiae643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。